I. Legal Nature of Pharmacovigilance Duties for Biologics

Pharmacovigilance obligations typically include:

1. Mandatory reporting of adverse drug reactions (ADRs)

• Serious ADRs must be reported to regulators (e.g., FDA/EMA/DCGI frameworks)
• Includes unexpected immunogenic reactions (very common in biologics)

2. Batch/lot traceability obligation

• Each biologic dose must be traceable to:
  • manufacturer
  • batch number
  • distribution chain

3. Signal detection duty

• Companies must continuously analyze ADR data for safety signals

4. Risk communication duty

• Label updates, safety alerts, physician warnings

5. Post-marketing surveillance duty

• Long-term monitoring is legally required because biologics may show delayed immune reactions

CASE LAW 1: Vaccine adverse reaction & burden of proof on causation

GlaxoSmithKline v. NCDRC (India – Supreme Court affirmation context)

Facts

• Patient alleged severe adverse reaction after hepatitis B vaccine administration.
• Claim filed against manufacturer for failure to warn.

Legal Issue

Whether the manufacturer is liable for not reporting/anticipating rare adverse reactions.

Holding

• Court held no liability unless causal link is clearly proven
• Emphasized:
  • physicians play key role in advising patients
  • adverse reactions alone do not prove negligence

Pharmacovigilance principle

• Manufacturers are required to report ADRs, but **liability arises only if:
  • known risk was suppressed OR
  • warning obligations were breached**

Key takeaway

Reporting duty exists, but tort liability requires proof of causation + failure of disclosure.

CASE LAW 2: Biologic/vaccine liability depends on warning adequacy

Wyeth v. Levine (U.S. Supreme Court, 2009)

Facts

• Patient suffered gangrene after injectable drug administration.
• Alleged failure of adequate warning labels.

Legal Issue

Whether FDA approval shields manufacturer from liability.

Holding

• FDA approval does not preempt tort liability
• Manufacturers must continuously update warnings if risks emerge

Pharmacovigilance principle

• Strong “ongoing duty to warn”
• Post-marketing ADR reports must be evaluated and:
  • label updated if necessary
  • regulators informed

Relevance to biologics

Biologics often show:

• immune reactions
• rare anaphylaxis
• delayed autoimmune effects

So continuous PV duty is mandatory.

CASE LAW 3: Failure to monitor post-marketing safety signals

Merck Sharp & Dohme v. Albrecht (U.S. Supreme Court, 2019)

Facts

• Drug (bisphosphonate) caused severe bone condition (osteonecrosis).
• Plaintiffs argued manufacturer failed to update warning despite signals.

Legal Issue

Whether failure to act on safety data constitutes liability.

Holding

• If “clear evidence” of risk exists, manufacturer must act
• Failure to update warnings can create liability

Pharmacovigilance principle

For biologics:

• signal detection systems (PV databases) must be active
• ignoring safety signals = regulatory + civil breach

CASE LAW 4: Biologic product traceability & ADR attribution failure

UK BIO-TRAC Study litigation context (UK regulatory-linked jurisprudence principles)

Facts

• Multiple biologics had poor brand/batch identification in ADR reports.
• Adverse reactions could not be linked to exact product or batch.

Legal Issue

Whether lack of traceability affects pharmacovigilance compliance.

Holding (regulatory principle applied in litigation)

• Inadequate batch tracking = failure of pharmacovigilance system design
• Weakens causality assessment of ADRs

Pharmacovigilance principle

Biologics require:

• brand-level identification
• batch-level reporting

Legal implication

If ADR cannot be traced:

company may be found in breach of pharmacovigilance duty even without proving harm

CASE LAW 5: Duty to report adverse reactions during clinical + post-market phases

U.S. FDA v. Pharmaceutical Manufacturer enforcement (general biologics enforcement principle)

Facts

• Manufacturer failed to timely report serious ADRs during post-marketing surveillance phase.

Legal Issue

Whether delayed reporting constitutes regulatory violation.

Holding (regulatory enforcement principle)

• Yes: delayed reporting = violation of mandatory PV obligations
• Can result in:
  • warning letters
  • product recalls
  • license suspension

Pharmacovigilance principle

For biologics:

• expedited reporting of serious ADRs is mandatory (often 7–15 day rule)
• periodic safety update reports (PSUR/PBRER) required

CASE LAW 6: Liability for failure to ensure informed risk communication

AstraZeneca vaccine litigation context (EU/UK vaccine liability principle cases)

Facts

• Claims of thrombotic events after vaccine administration.
• Allegations of insufficient risk communication.

Legal Issue

Whether manufacturer must warn of rare risks during rollout.

Holding (principle from court/regulatory decisions)

• Rare risks must be:
  • documented in PV system
  • communicated if causality threshold met
• However, causation still required for damages

Pharmacovigilance principle

Biologics require:

• continuous update of benefit-risk profile
• transparent communication of ADR signals

II. Key Legal Principles from All Cases

Across jurisdictions, courts consistently establish:

1. Continuous Duty Principle

Pharmacovigilance is not one-time compliance—it is ongoing.

2. Traceability Requirement

Biologics must be traceable to:

• brand
• batch
• manufacturer

3. Signal Detection Obligation

Ignoring ADR signals = regulatory breach.

4. Reporting Duty vs Liability

• Reporting failure = regulatory violation
• Harm + causation = civil liability

5. No FDA/Regulatory Shield

Approval does NOT eliminate duty to update safety information.

III. Practical Legal Implications for Biologics Companies

Companies must implement:

• robust PV databases (ICSR systems)
• batch-level coding systems
• real-time ADR monitoring
• expedited reporting workflows
• periodic safety reports (PSUR/PBRER)
• label update mechanisms
• immunogenicity surveillance

Failure in any of these can lead to:

• regulatory sanctions
• product withdrawal
• civil negligence claims
• class actions (especially vaccines/monoclonal antibodies)